Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection

Autores
Reiter, Russel; Sharma, Ramaswamy; Simko, Fedor; Dominguez Rodriguez, Alberto; Tesarik, Jan; Neel, Richard L.; Slominski, Andrzej T.; Kleszczynski, Konrad; Martín Giménez, Virna Margarita; Manucha, Walter Ariel Fernando; Cardinali, Daniel Pedro
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Numerous pharmaceutical drugs have been repurposed for use as treatments for COVID-19 disease. These drugs have not consistently demonstrated high efficacy in preventing or treating this serious condition and all have side effects to differing degrees. We encourage the continued consideration of the use of the antioxidant and anti-inflammatory agent, melatonin, as a countermeasure to a SARS-CoV-2 infection. More than 140 scientific publications have identified melatonin as a likely useful agent to treat this disease. Moreover, the publications cited provide the rationale for the use of melatonin as a prophylactic agent against this condition. Melatonin has pan-antiviral effects and it diminishes the severity of viral infections and reduces the death of animals infected with numerous different viruses, including three different coronaviruses. Network analyses, which compared drugs used to treat SARS-CoV-2 in humans, also predicted that melatonin would be the most effective agent for preventing/treating COVID-19. Finally, when seriously infected COVID-19 patients were treated with melatonin, either alone or in combination with other medications, these treatments reduced the severity of infection, lowered the death rate, and shortened the duration of hospitalization. Melatonin’s ability to arrest SARS-CoV-2 infections may reduce health care exhaustion by limiting the need for hospitalization. Importantly, melatonin has a high safety profile over a wide range of doses and lacks significant toxicity. Some molecular processes by which melatonin resists a SARS-CoV-2 infection are summarized. The authors believe that all available, potentially beneficial drugs, including melatonin, that lack toxicity should be used in pandemics such as that caused by SARS-CoV-2.
Fil: Reiter, Russel. University of Texas at San Antonio; Estados Unidos
Fil: Sharma, Ramaswamy. University of Texas at San Antonio; Estados Unidos
Fil: Simko, Fedor. Comenius University; Eslovaquia
Fil: Dominguez Rodriguez, Alberto. Hospital Universitario de Canarias; España
Fil: Tesarik, Jan. Margen Clinic; España
Fil: Neel, Richard L.. Alcasian Care Enterprises; Estados Unidos
Fil: Slominski, Andrzej T.. University Of Alabama At Birmingahm. School Of Medicine; Estados Unidos
Fil: Kleszczynski, Konrad. University Of Münster; Alemania
Fil: Martín Giménez, Virna Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Juan; Argentina. Universidad Catolica de Cuyo - Sede San Juan. Facultad de Ciencias de la Alimentación, Bioquímicas y Farmacéuticas. Instituto de Investigación en Ciencias Químicas; Argentina
Fil: Manucha, Walter Ariel Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Cátedra de Farmacología; Argentina
Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina
Materia
CORONAVIRUS
COVID-19
CYTOKINE STORM
HYPOXIA-INDUCIBLE FACTOR 1-Α
PHOSPHOLIPASE A2
SEPSIS
VIRAL INFECTION
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/203352
Acceder
id CONICETDig_39511a1c819337d236e5e5e301f19495
oai_identifier_str oai:ri.conicet.gov.ar:11336/203352
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infectionReiter, RusselSharma, RamaswamySimko, FedorDominguez Rodriguez, AlbertoTesarik, JanNeel, Richard L.Slominski, Andrzej T.Kleszczynski, KonradMartín Giménez, Virna MargaritaManucha, Walter Ariel FernandoCardinali, Daniel PedroCORONAVIRUSCOVID-19CYTOKINE STORMHYPOXIA-INDUCIBLE FACTOR 1-ΑPHOSPHOLIPASE A2SEPSISVIRAL INFECTIONhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Numerous pharmaceutical drugs have been repurposed for use as treatments for COVID-19 disease. These drugs have not consistently demonstrated high efficacy in preventing or treating this serious condition and all have side effects to differing degrees. We encourage the continued consideration of the use of the antioxidant and anti-inflammatory agent, melatonin, as a countermeasure to a SARS-CoV-2 infection. More than 140 scientific publications have identified melatonin as a likely useful agent to treat this disease. Moreover, the publications cited provide the rationale for the use of melatonin as a prophylactic agent against this condition. Melatonin has pan-antiviral effects and it diminishes the severity of viral infections and reduces the death of animals infected with numerous different viruses, including three different coronaviruses. Network analyses, which compared drugs used to treat SARS-CoV-2 in humans, also predicted that melatonin would be the most effective agent for preventing/treating COVID-19. Finally, when seriously infected COVID-19 patients were treated with melatonin, either alone or in combination with other medications, these treatments reduced the severity of infection, lowered the death rate, and shortened the duration of hospitalization. Melatonin’s ability to arrest SARS-CoV-2 infections may reduce health care exhaustion by limiting the need for hospitalization. Importantly, melatonin has a high safety profile over a wide range of doses and lacks significant toxicity. Some molecular processes by which melatonin resists a SARS-CoV-2 infection are summarized. The authors believe that all available, potentially beneficial drugs, including melatonin, that lack toxicity should be used in pandemics such as that caused by SARS-CoV-2.Fil: Reiter, Russel. University of Texas at San Antonio; Estados UnidosFil: Sharma, Ramaswamy. University of Texas at San Antonio; Estados UnidosFil: Simko, Fedor. Comenius University; EslovaquiaFil: Dominguez Rodriguez, Alberto. Hospital Universitario de Canarias; EspañaFil: Tesarik, Jan. Margen Clinic; EspañaFil: Neel, Richard L.. Alcasian Care Enterprises; Estados UnidosFil: Slominski, Andrzej T.. University Of Alabama At Birmingahm. School Of Medicine; Estados UnidosFil: Kleszczynski, Konrad. University Of Münster; AlemaniaFil: Martín Giménez, Virna Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Juan; Argentina. Universidad Catolica de Cuyo - Sede San Juan. Facultad de Ciencias de la Alimentación, Bioquímicas y Farmacéuticas. Instituto de Investigación en Ciencias Químicas; ArgentinaFil: Manucha, Walter Ariel Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Cátedra de Farmacología; ArgentinaFil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; ArgentinaBirkhauser Verlag Ag2022-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/203352Reiter, Russel; Sharma, Ramaswamy; Simko, Fedor; Dominguez Rodriguez, Alberto; Tesarik, Jan; et al.; Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection; Birkhauser Verlag Ag; Cellular and Molecular Life Sciences; 79; 143; 3-2022; 1-121420-682XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/10.1007/s00018-021-04102-3info:eu-repo/semantics/altIdentifier/doi/10.1007/s00018-021-04102-3info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:05:51Zoai:ri.conicet.gov.ar:11336/203352instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:05:51.881CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection
title Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection
spellingShingle Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection
Reiter, Russel
CORONAVIRUS
COVID-19
CYTOKINE STORM
HYPOXIA-INDUCIBLE FACTOR 1-Α
PHOSPHOLIPASE A2
SEPSIS
VIRAL INFECTION
title_short Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection
title_full Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection
title_fullStr Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection
title_full_unstemmed Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection
title_sort Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection
dc.creator.none.fl_str_mv Reiter, Russel
Sharma, Ramaswamy
Simko, Fedor
Dominguez Rodriguez, Alberto
Tesarik, Jan
Neel, Richard L.
Slominski, Andrzej T.
Kleszczynski, Konrad
Martín Giménez, Virna Margarita
Manucha, Walter Ariel Fernando
Cardinali, Daniel Pedro
author Reiter, Russel
author_facet Reiter, Russel
Sharma, Ramaswamy
Simko, Fedor
Dominguez Rodriguez, Alberto
Tesarik, Jan
Neel, Richard L.
Slominski, Andrzej T.
Kleszczynski, Konrad
Martín Giménez, Virna Margarita
Manucha, Walter Ariel Fernando
Cardinali, Daniel Pedro
author_role author
author2 Sharma, Ramaswamy
Simko, Fedor
Dominguez Rodriguez, Alberto
Tesarik, Jan
Neel, Richard L.
Slominski, Andrzej T.
Kleszczynski, Konrad
Martín Giménez, Virna Margarita
Manucha, Walter Ariel Fernando
Cardinali, Daniel Pedro
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv CORONAVIRUS
COVID-19
CYTOKINE STORM
HYPOXIA-INDUCIBLE FACTOR 1-Α
PHOSPHOLIPASE A2
SEPSIS
VIRAL INFECTION
topic CORONAVIRUS
COVID-19
CYTOKINE STORM
HYPOXIA-INDUCIBLE FACTOR 1-Α
PHOSPHOLIPASE A2
SEPSIS
VIRAL INFECTION
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Numerous pharmaceutical drugs have been repurposed for use as treatments for COVID-19 disease. These drugs have not consistently demonstrated high efficacy in preventing or treating this serious condition and all have side effects to differing degrees. We encourage the continued consideration of the use of the antioxidant and anti-inflammatory agent, melatonin, as a countermeasure to a SARS-CoV-2 infection. More than 140 scientific publications have identified melatonin as a likely useful agent to treat this disease. Moreover, the publications cited provide the rationale for the use of melatonin as a prophylactic agent against this condition. Melatonin has pan-antiviral effects and it diminishes the severity of viral infections and reduces the death of animals infected with numerous different viruses, including three different coronaviruses. Network analyses, which compared drugs used to treat SARS-CoV-2 in humans, also predicted that melatonin would be the most effective agent for preventing/treating COVID-19. Finally, when seriously infected COVID-19 patients were treated with melatonin, either alone or in combination with other medications, these treatments reduced the severity of infection, lowered the death rate, and shortened the duration of hospitalization. Melatonin’s ability to arrest SARS-CoV-2 infections may reduce health care exhaustion by limiting the need for hospitalization. Importantly, melatonin has a high safety profile over a wide range of doses and lacks significant toxicity. Some molecular processes by which melatonin resists a SARS-CoV-2 infection are summarized. The authors believe that all available, potentially beneficial drugs, including melatonin, that lack toxicity should be used in pandemics such as that caused by SARS-CoV-2.
Fil: Reiter, Russel. University of Texas at San Antonio; Estados Unidos
Fil: Sharma, Ramaswamy. University of Texas at San Antonio; Estados Unidos
Fil: Simko, Fedor. Comenius University; Eslovaquia
Fil: Dominguez Rodriguez, Alberto. Hospital Universitario de Canarias; España
Fil: Tesarik, Jan. Margen Clinic; España
Fil: Neel, Richard L.. Alcasian Care Enterprises; Estados Unidos
Fil: Slominski, Andrzej T.. University Of Alabama At Birmingahm. School Of Medicine; Estados Unidos
Fil: Kleszczynski, Konrad. University Of Münster; Alemania
Fil: Martín Giménez, Virna Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Juan; Argentina. Universidad Catolica de Cuyo - Sede San Juan. Facultad de Ciencias de la Alimentación, Bioquímicas y Farmacéuticas. Instituto de Investigación en Ciencias Químicas; Argentina
Fil: Manucha, Walter Ariel Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Cátedra de Farmacología; Argentina
Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina
description Numerous pharmaceutical drugs have been repurposed for use as treatments for COVID-19 disease. These drugs have not consistently demonstrated high efficacy in preventing or treating this serious condition and all have side effects to differing degrees. We encourage the continued consideration of the use of the antioxidant and anti-inflammatory agent, melatonin, as a countermeasure to a SARS-CoV-2 infection. More than 140 scientific publications have identified melatonin as a likely useful agent to treat this disease. Moreover, the publications cited provide the rationale for the use of melatonin as a prophylactic agent against this condition. Melatonin has pan-antiviral effects and it diminishes the severity of viral infections and reduces the death of animals infected with numerous different viruses, including three different coronaviruses. Network analyses, which compared drugs used to treat SARS-CoV-2 in humans, also predicted that melatonin would be the most effective agent for preventing/treating COVID-19. Finally, when seriously infected COVID-19 patients were treated with melatonin, either alone or in combination with other medications, these treatments reduced the severity of infection, lowered the death rate, and shortened the duration of hospitalization. Melatonin’s ability to arrest SARS-CoV-2 infections may reduce health care exhaustion by limiting the need for hospitalization. Importantly, melatonin has a high safety profile over a wide range of doses and lacks significant toxicity. Some molecular processes by which melatonin resists a SARS-CoV-2 infection are summarized. The authors believe that all available, potentially beneficial drugs, including melatonin, that lack toxicity should be used in pandemics such as that caused by SARS-CoV-2.
publishDate 2022
dc.date.none.fl_str_mv 2022-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/203352
Reiter, Russel; Sharma, Ramaswamy; Simko, Fedor; Dominguez Rodriguez, Alberto; Tesarik, Jan; et al.; Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection; Birkhauser Verlag Ag; Cellular and Molecular Life Sciences; 79; 143; 3-2022; 1-12
1420-682X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/203352
identifier_str_mv Reiter, Russel; Sharma, Ramaswamy; Simko, Fedor; Dominguez Rodriguez, Alberto; Tesarik, Jan; et al.; Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection; Birkhauser Verlag Ag; Cellular and Molecular Life Sciences; 79; 143; 3-2022; 1-12
1420-682X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/10.1007/s00018-021-04102-3
info:eu-repo/semantics/altIdentifier/doi/10.1007/s00018-021-04102-3
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Birkhauser Verlag Ag
publisher.none.fl_str_mv Birkhauser Verlag Ag
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269931875336192
score 13.13397

Publicaciones similares